At a glance
ClinicalIndex Comparison RecordN/ACompleted· 456 enrolled
Drug / intervention
Sorafenibdrug
Likely dose
Sorafenib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With FLT3-ITD Positive Acute Myeloid Leukemia
In Brief
An observational study evaluating Sorafenib for Acute Myeloid Leukemia and 2 related conditions. Completed, enrolled 456 participants across 1 site.
Detailed Summary
The purpose of this study is to reveal the influence of co-existing mutations on the efficacy of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for patients with FLT3-ITD AML.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Hematopoietic Stem Cell Transplantation
CountriesChina
CollaboratorsPeking University People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Zhujiang Hospital, Xiangya Hospital of Central South University, First People's Hospital of Chenzhou, The First Affiliated Hospital of Guangzhou Medical University, Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University, Xinqiao Hospital of Chongqing, First Affiliated Hospital of Zhejiang University
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
Primary CompletionJul 2018
Study CompletionDec 2020
First PostedMar 2021
TodayJul 2026
First PostedMar 9, 2021
Enrollment StartJan 1, 2012
Primary CompletionJul 21, 2018
Study CompletionDec 31, 2020
TodayJul 1, 2026
Enrollment to primary: 6.6 yearsPosted 5.3 years ago
Interventions
Sorafenibdrug
The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).